IDEXX Laboratories, Inc. (IDXX) Earnings Call Transcripts

IDEXX Laboratories, Inc.'s Latest Earnings Call - Q2 FY2026

In the second quarter of fiscal year 2026, IDEXX Laboratories reported revenue of approximately $4.7 billion, reflecting a 10% increase year-over-year, with earnings per share (EPS) of $4.27, marking a 15% growth on a comparable basis. Management raised their full-year revenue guidance to a range of $4.7 billion to $4.745 billion, driven by strong performance in CAG Diagnostics and an increase in operational performance, despite a $15 million headwind from foreign currency effects. The overall organic revenue growth outlook was also raised to 8.5% to 9.7%, indicating robust momentum in their companion animal business and diagnostic innovations.

Reported metrics

Guidance from management

Management raised their full-year revenue guidance to $4.7 billion to $4.745 billion and EPS guidance to $14.69 to $14.94 per share, reflecting strong operational performance and increased investments in growth.

What management said

It's general -- Dan, this is Mike. It's generally positive, and we've now seen this trend for multiple quarters in a row. And as I shared also, we're not just seeing it in our data, but we're hearing about it from our customers as well. So we think it's a consistent trend.

Yes. And I would just highlight, Mike. We do this on a number of fronts today already. We have core analyzers with our Catalyst chemistry analyzer in hematology as well as SediVue and inVue, and that's on top of some broader platforms like Cancer Dx that continue to take sector development work. So I think we're -- we've got a model here that we're highly focused on being able to do more than one thing at a time. And...

What analysts pressed on

Analysts raised concerns about the decline in U.S. same-store clinical visits, which could impact future growth. Management acknowledged pressures on discretionary wellness visits and the potential long-term effects on diagnostics utilization.

Main topics on the call

• Revenue Growth Acceleration — IDEXX achieved a revenue increase of approximately 10% year-over-year, with organic growth of 9%. Management noted, "CAG Diagnostics recurring revenues grew nearly 10% in Q2, including strong volume gains and net price r...
• Increased Guidance — Management raised the full-year revenue guidance to $4.7 billion to $4.745 billion, reflecting a $20 million operational improvement. They stated, "Strong second quarter performance supports an increase to our full year ...
• CAG Diagnostics Performance — CAG Diagnostics recurring revenue growth was highlighted, with a 10.3% organic increase, despite a decline in U.S. same-store clinical visits. Management emphasized that "pressure on wellness visits remains the primary c...
• Operating Margin Expansion — IDEXX reported a comparable operating margin gain of 110 basis points, with gross margins at 64%. Management noted, "Strong recurring revenue growth and favorable product costs enabled 12% comparable operating profit gai...

Read the full IDEXX Laboratories, Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 62 IDEXX Laboratories, Inc. earnings call transcripts on record, spanning January 31, 2020 to August 4, 2026. Based on this history, IDEXX Laboratories, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IDXX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

62

First call

January 31, 2020

Most recent

August 4, 2026

Reporting cadence

quarterly